Drug Profile


Alternative Names: ZP 1848

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Zealand Pharma
  • Class Glucagon-like peptides
  • Mechanism of Action Glucagon-like peptide 2 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Short bowel syndrome

Most Recent Events

  • 06 Feb 2017 Zealand Pharma completes enrolment in its phase II trial for Short bowel syndrome in USA
  • 03 Nov 2015 Phase-II clinical trials in Short bowel syndrome in USA (SC)
  • 17 Sep 2015 Zealand Pharma plans a phase II trial for Short Bowel Syndrome
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top